Appointment of Cost Auditors and Internal Auditors
CONCORDBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Concord Biotech Limited reported audited standalone financial results for Q4 and FY26. Revenue from operations declined to Rs. 1,05,507 lakhs from Rs. 1,20,009 lakhs in FY25. Profit before tax fell to Rs. 35,143 lakhs (FY25: Rs. 49,588 lakhs), and profit after tax stood at Rs. 26,327 lakhs (FY25: Rs. 37,296 lakhs). EPS declined to Rs. 25.17 from Rs. 35.65. The Board recommended a final dividend of Rs. 7.55 per equity share for FY26, subject to shareholder approval at AGM (record date: July 24, 2026). The company appointed M/s. Manubhai & Shah LLP as Internal Auditor and M/s. Dalwadi & Associates as Cost Auditor for FY27. Mrs. Ekta Gupta was appointed as Additional Independent Director for 5 years from June 1, 2026. Statutory auditors BSR & Co. LLP issued an unmodified opinion on the financial statements.
Revenue and profit declined year-over-year due to challenging market conditions. However, the company maintained dividend payments and received clean audit opinions, indicating robust financial controls. The appointment of experienced auditors and a new independent director strengthens governance.